

## **Program for DSKO's årsmøde 2020**

### **Hotel Nyborg Strand den 19.-21. marts**

**Torsdag den 19. marts**

Auditoriet

- |                      |  |
|----------------------|--|
| <b>15.30 - 16.30</b> | <b>Registrering, kaffe og kage</b>   |
| <b>16.30 - 16.35</b> | <b>Velkomst ved mødeudvalget</b>   |
| <b>16.35 - 19.00</b> | <b>FLASH – "Learn the dance moves"</b><br>Chairmen: Per Rugaard Poulsen, Danish Center of Particle Therapy and Brita Singes Sørensen, Aarhus University Hospital   |
| 16.35 - 17.20        | Clinical experience, perspectives and science<br>Jean Bourhis, Lausanne University Hospital, Schweiz   |
| <b>17.20 - 17.40</b> | <b>Pause</b>   |
| 17.40 - 18.40        | Elektron FLASH: Pre-clinical results (IS 1)<br>Kristoffer Petersson, Lund University Hospital, Sweden  |
| 18.40 - 19.00        | Biological effects and proton flash (IS 2)<br>Brita Singer Sørensen, Aarhus University Hospital, Denmark og Per Rugaard Poulsen, Danish Center of Particle Therapy |
| <b>19.00 - 20.00</b> | <b>Middag</b>  |
| <b>20.30 - ?</b>     | <b>DSKO's generalforsamling. Efter DSKO's generalforsamling afholdes sideløbende generalforsamlinger i FYO og DKOO</b>   |

**Fredag den 20. marts**

**07.00 - ?**

**DSKO's morgenløb**

5 km afpasset efter fysisk formåen

**08.00 – 09.00**

**Registrering**

Auditoriet

**09.00 - 13.10**

**Tumor Profiling: Personalized Medicine versus Treatment beyond Evidence**

Chairman: Kristoffer Rohrberg, Department of Oncology, Rigshospitalet

09.00

Welcome and introduction by the chairman

Kristoffer Rohrberg, Department of Oncology, Rigshospitalet

09.10

Genomic profile – an overview and status (IS 3)

Tim Svenstrup Poulsen, Department of Pathology, Copenhagen University Hospital Herlev and Gentofte

09.40

Minimal residual disease detection using circulating tumor DNA – can it redefine postoperative cancer management? (IS 4)

Claus Lindbjerg Andersen, Department of Molecular Medicine, Aarhus University Hospital

10.10

Novel targeted therapies and precision medicine (IS 5)

Kristoffer Rohrberg, Department of Oncology, Rigshospitalet

**10.40 - 11.10**

**Kaffepause**

11.10

Precision medicine: Towards genomically-driven clinical trials in solid tumors (IS 6)

Timothy Yap, Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center

12.10

3<sup>rd</sup> line treatment – does the light from the new 1<sup>st</sup> and 2<sup>nd</sup> line treatments overshadow the lack of evidence in 3<sup>rd</sup> line? (IS 7)

Karin Holmskov Hansen, Department of Oncology, Odense University Hospital

12.40

Discussion and summery

Chairman: Kristoffer Rohrberg, Department of Oncology, Rigshospitalet

Panel: Timothy Yap, Claus Lindbjerg Andersen, Tim Svenstrup Poulsen, Karin Holmskov Hansen

**13.00 - 14.00**

**Frokost**

**14.00 - 14.45**

**DSKO's onkologipris 2020**

**14.45 - 15.15**

**Kaffepause**

**15.15 - 16.20**

**Frie foredrag - præsentation af 5 udvalgte abstracts fra yngre forskere**

Bedømmere: Pernille Lassen, Aarhus Universitetshospital og Hans Skovgaard Poulsen, Rigshospitalet

15.15

Learning from patient involvement in a clinical study analyzing PET/CT in women with advanced breast cancer (PPO 1)

Marianne Vogsen, Odense Universitetshospital

15.25

Tumour infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early estrogen receptor positive breast cancer: analysis from a nationwide phase II DBCG trial (PPO 2)

Signe Korsgaard Skriver, Rigshospitalet

15.35

Early mortality after radical radiotherapy in head and neck cancer – a nationwide analysis from DAHANCA (PPO 3)

Kristian Hastoft Jensen, Rigshospitalet

15.45

Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression (PPO 4)

Malene Støchkel Frank, Rigshospitalet Sjællands Universitetshospital

15.55

Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (FTD/TPI or TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer (mCRC) (PPO 5)

Stine Braendegaard Winther, Odense Universitetshospital

Vandrehallen

**16.20 - 18.00**

**Poster session**

Bedømmere: Camilla Qvortrup, Rigshospitalet og Jesper Palshof, Herlev og Gentofte Hospital

Veranda og Terrasse

**19.00 - 02.00**

**Festmiddag med efterfølgende dans til levende musik**

## Lørdag den 21. marts

Auditoriet

### 09.00 - 11.30

#### Medicinrådet

09.00

Rådets ledelse, - hvad skal der til for et lægemiddel bliver godkendt. Beslutningsproces - fordele og ulemper ved Medicinrådet  
Jørgen Schøler Kristensen, Lægefaglig direktør, Aarhus Universitetshospital

09.25

Fagudvalgsarbejde - hvad består arbejdet i. Hvor stor er den reelle indflydelse fra fagudvalgene. Hvad er prisen/gevinsten ved som onkolog at være i fagudvalg  
Lotte Engell-Nørregård, medlem af fagudvalg for lungekræft og formand for DSKO

09.50

Sundhedsøkonomi - betydning og indflydelse på beslutningsprocesser i Medicinrådet  
Dorte Gyrd-Hansen, professor i sundhedsøkonomi, Syddansk Universitet

### 10.15 - 10.45

#### Kaffepause

10.45

Hvad har regioner ønsket at opnå ved at oprette Medicinråd. Er målet nået? Hvad er fremtiden for Medicinrådet?  
Karen Friis Bach, Formand for danske regioners sundhedsudvalg

11.10-11.30

Diskussion

### 11.30 - 12.00

#### Acta Oncologica pris

Mef Nilbert, Research director, **Danish Cancer Society Research Center (DCRC)**

12.00

**Mødet slutter**